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Objective: The aim of this study was to identify the princi-
pal determinants that are longitudinally associated with the 
performance of social roles in the first 3 years following a 
diagnosis of multiple sclerosis.
Design: Inception cohort with 5 measurements over 3 years.
Patients: A total of 156 patients recently diagnosed with mul-
tiple sclerosis.
Method: Performance of social roles was measured using the 2 
role functioning and the social sub-scales of the Medical Out-
come Study Short Form 36. Potential determinants (n = 43) 
were divided into the following clusters: patient and disease 
characteristics (n = 12), psychosocial characteristics (n = 10), 
basic functions (n = 18) and basic activities (n = 3). Multivari-
ate longitudinal regression analyses were performed with 
generalized estimating equations. A backwards selection 
procedure for every cluster per outcome reduced the large 
number of potential determinants. In order to determine 
whether longitudinal associations are present the selected de-
terminants were entered into an overall regression model. 
Results: Twenty-three candidate determinants were select-
ed. Vitality, measured with the SF36 sub-scale vitality, the 
T2-weighted supratentorial lesion load and the perceived 
amount of social support, measured with the Social Support 
List Discrepancies, were longitudinally associated with the 
performance of social roles in 2 or 3 of the models.
Conclusion: Vitality, the perceived amount of social support, 
and disease activity, i.e. the T2-weighted supratentorial le-
sion load, determine the performance of social roles in the 
early stages of multiple sclerosis.
Key words: multiple sclerosis, prognosis, social support, fatigue, 
disability evaluation.
J Rehabil Med 2008; 40: 151–157
Correspondence address: Vincent de Groot, Department of Re-
habilitation Medicine, PO Box 7057, NL-1007 MB Amsterdam, 
The Netherlands. E-mail address: v.degroot@vumc.nl
Submitted March 9, 2007; accepted October 4, 2007
INTROduCTION
Multiple sclerosis (MS) is characterized by variable neurologi-
cal symptomatology, which differs not only between patients, 
but also within patients over time. This makes it difficult to 
predict the clinical course of the disease, which poses an impor-
tant problem for clinicians treating patients with MS. Reviews 
of the studies that examined determinants of the clinical course 
showed that a progressive disease course, higher age at time 
of diagnosis, less than one year between relapses, and impair-
ments of pyramidal or cerebellar tracts are associated with an 
unfavourable disease course, whereas an exacerbation as first 
sign of MS, a high recovery rate after the first exacerbation 
and afferent or monoregional symptoms are associated with 
a more favourable disease course (1–4). Most studies have 
focused on neurological and locomotor function using the 
Expanded disability Status Scale (EdSS) (5) as outcome and 
the neurological deficits or magnetic resonance imaging (MRI) 
parameters as determinants. 
We were also interested in how patients with MS perform 
their social roles in the early stages of the disease. We used 
the International Classification of Functioning, Disability and 
Health (ICF) as a framework to study and explain the con-
sequences of MS for the patient (6). The ICF describes how 
patients live with their disease and therefore looks beyond 
mortality and disease. It is a classification of functioning that 
describes body functions and structures, activities and partici-
pation. Performance of social roles, i.e. participation, is mainly 
represented in the ICF chapters on interpersonal interactions 
and relationships, major life areas, and community, social and 
civic life (7).
Another frequently used framework to study the consequenc-
es of disease is the Health-Related Quality of Life framework 
(HR-QoL) (8, 9). The Medical Outcome Study Short Form 36 
(SF36) (10) is an example of a well-known frequently used 
HR-QoL measure. Although the ICF and HR-QoL frameworks 
represent different perspectives from which to look at function-
ing and health, it is possible to link items of HR-QoL measures 
to ICF constructs (11).
Most studies of the social consequences of MS have been 
cross-sectional (12–17). In the first 3 years after the diagnosis 
MS has been made, when for most patients mobility and mental 
health are relatively mildly affected, about 40% of the patients 
report considerable limitations in the performance of social 
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roles (18). For the whole group this percentage did not change 
in the first 3 years of the disease, but individual changes in the 
performance of social roles did occur. 
The aim of this study was to identify the principal determi-
nants that are longitudinally associated with the performance 
of social roles in the first 3 years after the diagnosis of MS.
METHOdS
Patients and design
The inclusion criteria were: diagnosis according to the Poser-criteria 
for definite MS less than 6 months previously (19); age range 16–55 
years; written informed consent. Patients with other neurological 
disorders, systemic or malignant neoplastic diseases besides MS were 
excluded. All consecutive potentially eligible patients visiting the 5 
participating outpatient clinics of neurology departments were asked 
to participate. One of the members of the research team regularly 
reminded the neurologists to ask all potentially eligible patients. A 
total of 174 patients fulfilled the inclusion criteria and were asked to 
participate. Eighteen declined to participate. A cohort of 156 diagnosed 
patients was recruited (in 1998–2000) and prospectively followed for 3 
years. Measurements took place at inclusion (between time of diagnosis 
and 6 months later), after 6 months, and after 1, 2 and 3 years. In case 
of a relapse, measurements were postponed for a few weeks until the 
relapse had subsided. Patients received a set of postal questionnaires 
that took them approximately 45 min to complete. Subsequently, they 
were visited at home in order to minimize dropouts. during this 2-hour 
home-visit the questionnaires were checked for completeness, and the 
other tests were performed. Three well-trained physical therapists and 
one well-trained physician performed the scoring.
Outcome measures
We used the SF36 (10) sub-scales role physical (SF36rp), role emo-
tional (SF36re) and social functioning (SF36sf) to measure the per-
formance of social roles. Validity and reliability have been extensively 
studied and found to be good (10). 
Determinants
Forty-three potential determinants, divided over 4 clusters that 
were based on the ICF (6), were identified using a literature search. 
Almost all determinants were measured on each point in time. MRI 
data were only available at the baseline measurement. Scores on the 
questionnaires and cognitive tests were linearly transformed into a 
0–10 scale.
The cluster “patient and disease characteristics” contains the follow-
ing determinants: age (per 10 years), gender, co-morbidity measured 
with the Cumulative Illness Rating Scale (range 0 = no co-morbidity 
to 10=maximal co-morbidity score) (20), whether the disease starts 
with an exacerbation (non-relapse onset (NRO) vs relapse onset (RO)), 
the self-reported number of exacerbations in the previous period, time 
since first symptoms (logarithmically transformed), first neurological 
symptom (pyramidal, cerebellar, brainstem, sensory, bowel or bladder, 
optical; analysed as 5 dummy variables), T1-hypointense and T2-
weighted (supra- and infratentorial) lesion loads in cm3 (MRI) (21), 
and number of lesions in the spinal cord (MRI) (22). 
The cluster “psychosocial characteristics” contains 10 determinants. 
Locus of Control is measured with the sub-scales internal, physician 
and chance of the Multidimensional Health Locus of Control Scale 
(23); sub-scale scores range from 0 = lowest to 10 = highest locus of 
control score. Personality traits were measured with the sub-scales 
psychoticism, extraversion and neuroticism of the Eysenck Person-
ality Questionnaire (24); sub-scale scores range from 0 = lowest to 
10 = highest score on the personality trait. Two methods to measure 
social support were used. The amount of social support, i.e. a meas-
ure of the quantity of supportive interactions, was measured with the 
Social Support List Interactions (25); scores range from 0 = no sup-
port to 10 = maximal social support. The perceived amount of social 
support, i.e. a measure of the extent to which the available supportive 
interactions cover the patient’s need for social support, was measured 
with the Social Support List discrepancies (25); scores range from 
0 = needs are not covered at all to 10 = needs are completely covered. 
We also assessed whether the patient had a partner, and whether the 
patient had children.
The cluster “basic functions” consists of 18 determinants. The in-
volvement of the different neurological systems was measured with 
the Functional System (FS) scores, ranging from 0 = no impairment 
to 5 or 6 = maximal impairment) of the EdSS (5): the FS optical, the 
FS brainstem, the FS cerebellar, the FS bowel and bladder, the FS 
pyramidal, the FS sensory, the FS mental and the FS other. Cognitive 
function was measured with the Brief Repeatable Battery of cogni-
tive tests for MS (26), which includes the sub-scales Consistent Long 
Term Retrieval and Long Term Storage of the Selective Reminding 
Test measuring verbal learning and memory, the 10/36 Spatial Recall 
Test measuring visuospatial learning and delayed recall, the Symbol 
digit Modalities Test measuring sustained attention and concentration, 
the Paced Auditory Serial Addition Test measuring sustained atten-
tion and information processing speed, and the Word List Generation 
measuring verbal fluency; the scores range from 0 = worst possible to 
10 best possible score. Fatigue was measured with the Fatigue Severity 
Scale (27), which measures the patient’s perceived level of fatigue in a 
variety of situations; scores range from 0 = lowest possible to 10 =high-
est possible fatigue score. Vitality, i.e. the presence of energy and the 
absence of fatigue, was measured with the SF36 sub-scale vitality;(10) 
scores range from 0 = lowest to 10 = maximal vitality score. Pain was 
assessed with the SF36 sub-scale bodily pain;(10) scores range from 
0 = minimal to 10 = maximal pain score. Because we used the ICF as 
framework, which classifies pain and vitality as body functions, we 
think it is justified to use these variables as independent variables in a 
regression analysis, even though they are, like the outcome measures, 
a sub-scale of the SF36.
Finally, a cluster “basic abilities” was created that consists of 3 
determinants. dexterity was measured with the Action Research Arm 
test (28), and the Nine Hole Peg Test (29). Ambulation was assessed 
with the10-m Timed Walk Test (30). Because we measured patients at 
home, we had to find a suitable 10-m stretch in or around the house of 
the patient. At subsequent measurements we used the same stretch. 
Analysis
Because the scores on the SF36 sub-scales are skewed, we had to 
dichotomize them. We used data of an age-matched dutch reference 
population (10) to determine the cut-off for each sub-scale. We cal-
culated the mean –1.96 standard deviation (Sd) with these reference 
data for each sub-scale. SF36 sub-scale scores in our data that were 
worse than this cut-off were classified as aberrant. 
Statistical analyses were performed using binomial generalized 
estimating equations (GEE) (31) from the Statistical Package for 
Interactive data Analysis version 6.05 from the Statistical Computing 
Laboratory, because for dichotomous outcomes GEE results are more 
stable than Hierarchical Linear Modelling (32). Time was modelled as 
a continuous variable expressed in years in every regression model. 
The analysis was performed in 3 steps:
•	 Step 1. A backwards selection procedure for every cluster per out-
come was used to reduce the large number of potential determinants. 
Because statistical modelling in small data sets is susceptible to bias 
(33), we used in this step a liberal p-value of 0.10.
•	 Step 2. The determinants identified in step 1 were entered into an 
overall regression model, and reduced using a backwards selection 
procedure with a significance level of 0.05. Results of the final re-
gression models are presented as odds ratios (OR), because we were 
interested in the strength of the relationship of the determinant with 
the outcome. In this step it is important to construct models with 
determinants that are significantly associated with the outcomes.
• Step 3. Because these ORs contain information about the between-
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subject differences (cross-sectional relationship at each time point) 
as well as information about the within-subject changes (longitu-
dinal relationship, i.e. is a change in the determinant for a patient 
associated with a change in the outcome for that same patient) 
(34), autoregressive models were created to disentangle the relative 
contribution of the between-subject differences and the within-
subject changes to the ORs. For this purpose, the outcome of the 
previous measurement was added as determinant to the regression 
models obtained in step 2. The power of the autoregression models 
is lower than the power of the standard models, which means that 
the confidence intervals may be wider and may occasionally be not 
significant any longer. However, because the aim of this step in the 
analysis is to determine whether associations can be attributed to 
within- or between-subject changes, we focus on the interpretation 
of changes in the ORs and not on the level of significance. When the 
ORs of the standard and autoregressive models are roughly similar, 
the effect can be attributed to within-subject changes (longitudinal 
relationship). When the ORs are closer to 1 (no effect) in the auto-
regressive model as compared with the standard model, the effect 
can be attributed to between-subject differences (cross-sectional 
relationship). Thus, 6 regression models were created (a standard 
and an autoregressive model for 3 outcome measures).
RESuLTS
Patients
We included 128 patients in the RO group: mean age 36.25 
years (Sd 9.24), 87 (68%) women, median symptom dura-
tion 2.12 (interquartile range (IQR) 0.71–4.70) years, median 
disease duration 0.26 (IQR 0.15–0.41) years, median number 
of exacerbations 2 (IQR 2–3), and median EdSS 2.0 (IQR 
2.0–3.0); and 28 patients in the NRO group: mean age 43.74 
years (Sd 8.64), 14 (50%) women, median symptom duration 
2.38 (IQR 1.15–3.60) years, median disease duration 0.23 
(IQR 0.14–0.33) years, and median EdSS 3.0 (IQR 2.5–4.0). 
At time of diagnosis 8 patients (5%) in the RO group had a 
secondary progressive disease type with a long time since first 
symptoms (median 7.50 (IQR 3.35–14.51)). Looking carefully 
at their history, it became clear that for all of these patients 
there was a delay in making the diagnosis, either caused by the 
patient or the physician. At the baseline measurement, 6% of 
the patients and, at the last measurement, 30% of the patients 
with RO were receiving disease-modifying drugs.
Most characteristics comply with the expected pattern: more 
women than men in the RO group, more men than women in the 
NRO group, and more severe EdSS scores in the NRO group. 
Seven patients were lost to follow-up (3 after one year, one 
after 2 years and 3 after 3 years). Of the 149 patients with a 
complete 3-year follow-up 15 measurements were missing.
Table I shows the median (IQR) and the percentage of pa-
tients with aberrant scores of the outcomes SF36rp, SF36re 
and SF36sf for the RO and NRO group at each measurement. 
In a healthy reference population 5% has aberrant scores. Our 
population clearly showed more problems with regard to per-
formance of social roles as measured with the SF36rp, SF36re 
and SF36sf. The most pronounced deviation was found for the 
sub-scale SF36rp, followed by SF36sf and SF36re.
Reduction of determinants
In the first step of the analysis, where we analysed the de-
terminants for every cluster per outcome measure separately 
(using a p-value < 0.10), the list of 43 potential determinants 
was reduced to a list of 11–13 determinants for each outcome 
(Table II). In total, 23 determinants were associated with one 
or more of the outcome measures. 
Construction of standard models
Results of the second step in the analysis, the construction of the 
standard models, can be found in Table III. The OR is the ratio of 
the probability that the patient does not deviate from the norm to 
Table I. Performance of social roles of recently diagnosed patients with multiple sclerosis (n = 156). Median (interquartile range; IQR) scores 
and percentage (%) of patients with aberrant scores at each measurement
Baseline 6 months 1 year 2 years 3 years
SF36 role physical
RO (n = 128) Median (IQR) 50 (0–100) 75 (0–100) 75 (18.8–100) 75 (6.3–100) 75 (0–100)
% aberrant 37.5 35.5 36.1 31.0 33.9
NRO (n = 28) Median (IQR) 25 (0–75) 25 (0–93.8) 25 (0–100) 25 (0–81.3) 25 (25–75)
% aberrant 42.9 42.9 46.2 46.2 30.4
SF36 role emotional
RO (n = 128) Median (IQR) 100 (33.3–100) 100 (66.7–100) 100 (66.7–100) 100 (66.7–100) 100 (66.7–100)
% aberrant 13.3 14.5 9.8 15.3 12.1
NRO (n = 28) Median (IQR) 100 (41.7–100) 100 (41.7–100) 100 (58.3–100) 100 (66.7–100) 100 (100–100)
% aberrant 7.1 10.7 15.4 3.8 8.7
SF36 social functioning
RO (n = 128) Median (IQR) 75 (62.5–100) 87.5 (62.5–100) 87.5 (62.5–100) 87.5 (62.5–100) 75 (62.5–100)
% aberrant 11.7 10.5 12.3 12.7 15.3
NRO (n = 28) Median (IQR) 87.5 (62.5–100) 75 (40.6–100) 62.5 (46.9–87.5) 62.5 (62.5–87.5) 62.5 (62.5–87.5)
% aberrant 17.9 28.6 23.1 11.5 4.3
SF36: Medical Outcome Study Short Form 36; RO: relapse onset; NRO: non-relapse onset;  % aberrant: % of patients with aberrant SF36 sub-scale 
scores. Because the scores on the SF36 sub-scales are skewed, we had to dichotomize them. data of an age-matched dutch reference population 
were used to determine the cut-off for each sub-scale. The mean –1.96 standard deviation was calculated with these reference data for each sub-
scale. SF36 sub-scale scores in our data that were worse than this cut-off were classified as aberrant.
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the probability that he does in reference to a score of zero on the 
determinant. Because we standardized most of the scales of the 
determinants, the ORs in Table III can be compared with each 
other in order to determine which determinant has the strongest 
association with the outcome of interest. An OR > 1 indicates that 
a patient with a higher score on the determinant is more likely 
to have a normal performance of social roles, while an OR < 1 
indicates that a patient with a higher score on the determinant is 
less likely to have a normal performance of social roles. When 
the increase in the score of the determinant is more than one 
point, the OR can be calculated. First, the OR from Table III is 
converted to the original logistic coefficient by taking the natural 
log (ln). This logistic coefficient is then multiplied by the score 
on the determinant, and finally e is raised to the power of this 
coefficient. In formula: e (score × ln [OR in Table III]). 
Vitality, measured with the SF36vt, is associated with all 
outcome measures (ORs 1.63–2.25), indicating that patients 
reporting more vitality have higher odds to have a normal 
performance of social roles. Besides this being a consistent 
association, it is also the strongest association among the 
determinants studied.
The T2-weighted supratentorial lesion load (ORs 0.71 and 
0.78) and the perceived amount of social support (ORs 1.19 and 
1.31), i.e. the extent to which the available supportive interac-
tions cover the patient’s need for social support, are associated 
with 2 outcome measures, indicating that patients who have a 
higher T2-weighted supratentorial lesion load have lower odds 
and that patients who perceive more social support have higher 
odds to have a normal performance of social roles.
The other determinants are associated with only one of the 
social roles. Fatigue (OR 0.81), exacerbations (OR 0.79) and 
the amount of social support (OR 0.71), i.e. the quantity of 
supportive interactions, are associated with the outcome role 
physical, indicating that more fatigued patients, patients who 
have experienced more exacerbations and patients having a 
large amount of social support are less likely to have normal 
role physical functioning. Gender (OR 0.16), verbal learning 
and memory (OR 1.26), psychoticism (OR 0.66), neuroticism 
(OR 0.78), and locus of control physician (OR 1.45) are as-
sociated with the outcome role emotional, indicating that male 
patients, patients who have better verbal learning and memory 
and patients who rely more heavily on their physician are 
more likely to have normal role emotional functioning, and 
patients who have higher psychoticism and neuroticism scores 
are less likely to have normal role emotional functioning. The 
functional system score cerebellar (OR 0.70) is associated 
with the outcome social functioning, indicating that patients 
with more cerebellar symptoms are less likely to have normal 
social functioning.
Construction of autoregressive models
In step 3, the construction of the autoregressive models, 
most odds ratios are similar to the odds ratios in the standard 
models, indicating that the association can be attributed to 
within-subject changes (longitudinal relationship). However, 
the association of the perceived amount of social support with 
the outcome role physical is somewhat reduced, indicating 
that this association is based on both between-subject differ-
ences (cross-sectional relationship) and within-subject changes 
(longitudinal relationship). 
dISCuSSION
The most important determinants associated with the performance 
of social roles as measured with the SF36rp, SF36re and SF36sf 
are vitality, the perceived amount of social support, and the T2-
weighted supratentorial lesion load. The associations are based 
on within-subject changes, which means that a change in the 
determinant for a particular patient in the 3-year study period is 
associated with a change in the outcome for that same patient.
until now, studies that looked for determinants associated 
with the performance of social roles have predominantly been 
cross-sectional (15–17). An important strength of our study is 
its longitudinal design and analysis, and the simultaneous as-
sessment of an extensive set of determinants, each measuring 
Table II. Candidate determinants for final regression models
determinants per cluster SF36rp SF36re SF36sf
Patient and disease characteristics
Co-morbidity + +
Self-reported number of exacerbations + +
Gender +
MRI: T2-weighted supratentorial lesion 
load
+ +
Psychosocial characteristics
Locus of control: internal +
Locus of control: physician +
Personality trait: neuroticism + + +
Personality trait: psychoticism +
Social support: amount of social support +
Social support: perceived social support + + +
Basic functions
Cognition: sustained attention and 
concentration
+
Cognition: verbal learning and memory: 
CLTR
+
Cognition: verbal learning and memory: 
LTS
+
Cognition: visuospatial learning delayed 
recall
+
Fatigue +
Functional systems: cerebellar +
Functional systems: mental + + +
Functional systems: optical +
Functional systems: pyramidal +
Pain +
Vitality + + +
Basic abilities
dexterity: ARA +
dexterity: NHPT + +
SF36rp: Medical Outcome Study Short Form 36 sub-scale role 
physical; SF36re: SF36 sub-scale role emotional; SF36sf: SF36 sub-
scale social functioning; CLTR: Consistent Long Term Retrieval; LTS: 
Long Term Storage; ARA: Action Research Arm Test; NHPT: Nine 
Hole Peg Test; MRI: magnetic resonance imagining.
+ p-value < 0.10 in stepwise backwards selection procedure per cluster 
per outcome.
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a distinct construct, and outcome measures, which cover dif-
ferent aspects of the performance of social roles. This enables 
a direct comparison of the adjusted association of several 
determinants with the outcome measures. In this way, the most 
important determinants are selected, and it becomes clear which 
determinants are redundant. Furthermore, it is possible to use 
longitudinal data analysis techniques, which enable investiga-
tion of the contribution of between-subject differences (cross-
sectional relationship) and within-subject changes (longitudinal 
relationship) to the regression coefficients.
A possible weakness is the use of multiple raters. due to the 
6-year study period 3 physical therapists had to be trained by 
the research physician (VdG) to perform the measurements, 
probably at the risk of reducing reliability of the measure-
ments. For the measures that require skilled raters, such as 
the cognitive tests and the scoring of the functional systems 
of the EdSS, an intensive training was given, and new raters 
were supervised until they were adequately able to perform 
the measurements. 
Another possible weakness is the relatively small sample 
size of 156 patients. Modelling in small samples might influ-
ence the selection of variables. Simulation experiments have 
shown that stepwise methods have limited power to select 
important determinants, and, on the other hand, carry the risk 
that one or more (almost) random determinants are selected, 
since multiple comparisons are made (33). Furthermore, the 
estimate of the regression coefficient might be biased (33). In 
order to minimize these effects, we used longitudinal regres-
sion analysis (GEE) to describe the longitudinal relationships. 
GEE has the important advantage that all available data are 
used, which increases the power to detect subtle relationships. 
Furthermore, we used a more liberal p-value of 0.10 for the 
initial selection of candidate determinants. 
Ideally, in a longitudinal study the treatment of the patients 
should either be standardized or withheld. Of course, this can-
not be justified in patients with a chronic progressive disease 
like MS, for which effective therapy was available and became 
available during the study (35, 36). disease-modifying drugs 
reduce the rate of relapse by approximately 30%, but they have 
not yet convincingly been shown to reduce disability progres-
sion, and certainly not in such a short study period of 3 years. 
Therefore, we think that our results are still very useful.
This study shows some consistent findings across the differ-
ent aspects of the performance of social roles, which suggests 
that the determinants vitality, the perceived amount of social 
support and the T2-weighted supratentorial lesion load might 
play a role in the development of problems with regard to the 
performance of social roles. Previously, we have studied the 
initial course of daily functioning in the same cohort (18). We 
showed that the differences regarding the performance of social 
roles between the RO and NRO groups were not significant, 
and that inclusion of the 8 secondary progressive patients did 
not confound our results. Also, we studied the course of mental 
health. We expected that mental health was greatly reduced in 
the first period after the diagnosis has been made, and that it 
would gradually recover. However, we found that mental health 
was relatively unaffected, which indicates that mental health 
cannot explain the reduced performance of social roles.
However, the results of this study should be interpreted with 
caution, because causal inferences cannot be made. From a 
clinical point of view it can easily be understood that dimin-
ished vitality, i.e. a lack of energy, leads to problems with 
regard to the performance of social roles. Patients might have 
problems to continue sports or leisure activities, skip social 
activities with family or friends, or are no longer able to work 
a full day (37). It is surprising that vitality was selected in all 
Table III. Determinants of the performance of social roles in recently diagnosed patients with multiple sclerosis. Odds ratios (95% CI) for standard 
and autoregression models.
determinant
SF36rp SF36re SF36sf
Standard Auto-regression Standard Auto-regression Standard Auto-regression
Vitality* 1.84 (1.58–2.15) 1.92 (1.65– 2.24) 1.63 (1.24– 2.15) 1.80 (1.37– 2.37) 2.25 (1.85– 2.73) 2.16 (1.74– 2.68)
Perceived social support* 1.19 (1.02–1.39) 1.08 (0.91– 1.29) 1.31 (1.16– 1.47) 1.25 (1.11– 1.4)
T2-weighted supratentorial lesion 
load (cm3)
0.78 (0.62–0.99) 0.82 (0.65– 1.04) 0.71 (0.57– 0.88) 0.54 (0.43– 0.67)
Self-reported number of 
exacerbations
0.79 (0.66–0.95) 0.65 (0.46– 0.93)
Amount of social support* 0.71 (0.58–0.88) 0.77 (0.61– 0.98)
Fatigue* 0.81 (0.71–0.93) 0.86 (0.74– 1.01)
Gender† 0.16 (0.06– 0.44) 0.11 (0.05– 0.25)
Verbal learning and memory* 1.26 (1.01– 1.56) 1.19 (0.88– 1.59)
Functional systems: cerebellar‡ 0.70 (0.51– 0.97) 0.76 (0.51– 1.11)
Psychoticism* 0.66 (0.46– 0.96) 0.72 (0.53– 0.98)
Neuroticism* 0.78 (0.69– 0.88) 0.79 (0.72– 0.88)
Locus of control physician* 1.45 (1.14– 1.83) 1.25 (0.98– 1.58)
Outcomes are dichotomized using the mean –1.96 standard deviation of a healthy dutch reference population; for all outcomes 1= normal social 
functioning and 0 = aberrant social functioning. SF36rp = Medical Outcome Study Short Form 36 sub-scale Role Physical; SF36re = SF36 sub-
scale Role Emotional; SF36sf = SF36 sub-scale Social Functioning.
*Scaled from 0 to 10.
†Female is reference category.
‡Scaled from 0 to 6.
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models, while fatigue, measured with the FSS, was selected 
in the role physical model only. The items of the vitality sub-
scale of the SF36 address feelings of fatigue or energy levels, 
while the items of the FS address fatigue in the context of the 
consequences of this fatigue for functioning. This conceptual 
difference in the assessment of fatigue is reflected in the cor-
relation of 0.71 between the FS and the vitality sub-scale of 
the SF36. Although our binomial GEE models were stable, 
this correlation may have led to some competition as to which 
determinant was selected in the final model (collinearity). 
Although the relationship between an increase in T2-weighted 
supratentorial lesion load and more problems with regard to 
the performance of social roles is also imaginable, the precise 
mechanism is less obvious. A higher T2-weighted supratentorial 
lesion load might be an indicator of cognitive dysfunction (38), 
or might indicate that there has been more disease activity (ac-
cumulated pathological changes). In our sample, however, there 
was no association of T2-weighted supratentorial lesion load 
with time since first symptoms, which indicates that T2-weighted 
lesion load is not an indicator of time since first symptoms.
The interpretation of the associations with the 2 social sup-
port scales is complex, and further complicated by the fact that 
the associations of both scales point in opposite directions. The 
correlation between both scales is low (rho = 0.44), indicating 
that they measure different constructs, and contribute inde-
pendently to the results of the analyses. The association with 
the perceived amount of social support can be interpreted in 
2 ways. It might be that a patient, who experiences a lack of 
social support is less inclined to participate in social activities. 
However, the relationship might also be interpreted in the op-
posite direction: a patient, who shows social dysfunction for 
any reason, experiences this as a lack of social support. The 
interpretation of the finding that patients who report a greater 
amount of social support have higher odds of problems with 
regard to the performance of social role should probably be 
that problems with regard to the performance of social roles 
lead to an accumulation of supportive interactions, and thus 
an increase in the amount of social support. Finally, an overall 
interpretation of social support might be that a low perceived 
amount of social support leads to a compensatory increase in 
the amount of social support, which is, unfortunately, not suf-
ficient to normalize the performance of social roles.
Future studies should focus on further clarification of the 
possible causal relationship between vitality, the perceived 
amount of social support and the T2-weighted supratentorial 
lesion load, and the performance of social roles. It would be 
very interesting to design trials that study the effect of inter-
ventions that are developed to influence the above mentioned 
determinants. Trials showing that these interventions lead to 
improved performance of social roles would provide strong 
evidence for a causal relationship.
But first, more longitudinal studies are needed to build a 
broader evidence base. Our results might aid the selection of 
determinants for these studies. Since we realize that the 3-year 
follow-up of this cohort is relatively short, we intend to extend 
the follow-up. This would enable a description of the course 
of the performance of social roles during the later stages of 
the disease and a study of the determinants associated with the 
performance of social roles in these later stages. Patients in our 
incidence cohort are currently only relatively mildly disabled, 
which will certainly change with longer disease duration. This 
will probably have consequences for the relative importance 
of the determinants we have studied.
Clinicians caring for patients with MS will be confronted 
with patients who are limited in their performance of social 
roles. Interventions to reduce the development of new lesions 
are available and implemented in clinical practice. Our results 
indicate that vitality and the perceived amount of social support 
might also be important factors to improve in these patients. 
Isolated interventions to improve vitality, such as amantadine 
(37), energy conservation techniques (39) and aerobic train-
ing (40), are available, but evidence regarding their efficacy 
is not conclusive. different interventions to improve the per-
ceived amount of social support are also available, but again 
the evidence is not conclusive (41). Furthermore, as argued 
above, is has not been shown that these interventions lead to 
improved performance of social roles. However, it has been 
shown that outpatient as well as home-based multidisciplinary 
rehabilitation programmes can lead to improvements in the 
performance of social roles (42–44). These studies looked at 
the rehabilitation programme as a whole and did not focus on 
specific elements in these programmes. It is very likely, though, 
that these programmes contained elements addressing vitality 
and the perceived amount of social support.
In conclusion, vitality, the perceived amount of social sup-
port, and disease activity, i.e. the T2-weighted supratentorial 
lesion load, determine the performance of social roles in the 
early stages of MS.
ACkNOWLEdGEMENTS
This study was presented as a poster at the Rehabilitation in Multiple 
Sclerosis meeting in Tallinn, Estonia, May 2005.
The Netherlands Organization for Scientific Research (NWO 940-33-
009) supported this study.
This study has been performed on behalf of the Functional prognostica-
tion and disability (FuPro) study group: G. J. Lankhorst, J. dekker, A. J. 
dallmeijer, M. J. IJzerman, H. Beckerman, V. de Groot: Vu university 
Medical Center Amsterdam (project coordination); A. J. H. Prevo, E. 
Lindeman, V. P. M. Schepers: university Medical Center, utrecht; H. J. 
Stam, E. Odding, B. van Baalen: Erasmus Medical Center, Rotterdam; 
A. Beelen, I. J. M. de Groot: Amsterdam Medical Center, Amsterdam. 
We would like to thank the neurologists in the participating hospitals 
(Vu university Medical Center, Academic Medical Center Amsterdam, 
Saint Lucas Andreas Hospital Amsterdam, OLVG Hospital Amsterdam, 
Erasmus Medical Center Rotterdam) for recruiting the patients, and M. 
Jacobs – Van der Bruggen, M. Schothorst, and T. Wedding for perform-
ing the measurements.
REFERENCES
1. Runmarker B, Andersen O. Prognostic factors in a multiple scle-
rosis incidence cohort with twenty-five years of follow-up. Brain 
1993; 116: 117–134.
J Rehabil Med 40
157Determinants of the performance of social roles in multiple sclerosis
2. Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, 
Baskerville J, Ebers GC. The natural history of multiple sclerosis: 
a geographically based study. 3. Multivariate analysis of predictive 
factors and models of outcome. Brain 1991; 114: 1045–1056.
3. Amato MP, Ponziani G. A prospective study on the prognosis of 
multiple sclerosis. Neurol Sci 2000; 21: S831–S838.
4. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors 
and progression of irreversible disability in multiple sclerosis: an 
amnesic process. Brain 2003; 126: 770–782.
5. kurtzke JF. Rating neurologic impairment in multiple sclerosis: 
an expanded disability status scale (EdSS). Neurology 1983; 33: 
1444–1452.
6. WHO. International Classification of Functioning, Disability and 
Health: ICF. Geneva: WHO; 2001.
7. Geuskens GA, Burdorf A, Hazes JM. Consequences of rheumatoid 
arthritis for performance of social roles – a literature review. J 
Rheumatol 2007; 34: 1248–1260.
8. Anderson RT, Aaronson Nk, Wilkin d. Critical review of the 
international assessments of health- related quality of life. Quality 
of Life Research 1993; 2: 369–395.
9. Romney dM, Evans dR. Toward a general model of health-related 
quality of life. Quality of Life Research 1996; 5: 235–241.
10. Aaronson Nk, Muller M, Cohen Pd, Essink-Bot ML, Fekkes M, 
Sanderman R, et al. Translation, validation, and norming of the 
dutch language version of the SF-36 Health Survey in commu-
nity and chronic disease populations. J Clin Epidemiol 1998; 51: 
1055–1068.
11. Cieza A, Stucki G. Content comparison of health-related quality of 
life (HRQOL) instruments based on the international classification 
of functioning, disability and health (ICF). Qual Life Res 2005; 
14: 1225–1237.
12. Murphy N, Confavreux C, Haas J, konig N, Roullet E, Sailer M, 
et al. Quality of life in multiple sclerosis in France, Germany, and 
the united kingdom. J Neurol Neurosurg Psychiatry 1998; 65: 
460–466.
13. Paltamaa J, Sarasoja T, Wikstrom J, Malkia E. Physical functioning 
in multiple sclerosis: a population-based study in central Finland. 
J Rehabil Med 2006; 38: 339–345.
14. Rothwell PM. Quality of life in multiple sclerosis. J Neurol Neu-
rosurg Psychiatry 1998; 65: 433.
15. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality 
of life in multiple sclerosis? QJM 2004; 97: 671–676.
16. Brunet dG, Hopman WM, Singer MA, Edgar CM, Mackenzie TA. 
Measurement of health-related quality of life in multiple sclerosis 
patients. Can J Neurol Sci 1996; 23: 99–103.
17. Somerset M, Peters TJ, Sharp dJ, Campbell R. Factors that 
contribute to quality of life outcomes prioritised by people with 
multiple sclerosis. Qual Life Res 2003; 12: 21–29.
18. de Groot V, Beckerman H, Lankhorst GJ, Polman CH, Bouter 
LM. The initial course of daily functioning in multiple sclerosis: 
a three-year follow-up study. Mult Scler 2005; 11: 713–718.
19. Poser CM, Paty dW, Scheinberg L, Mcdonald WI, davis FA, Ebers 
GC, et al. New diagnostic criteria for multiple sclerosis: guidelines 
for research protocols. Ann Neurol 1983; 13: 227–231.
20. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J 
Amer Geriatrics Soc 1968; 16: 622–626.
21. kalkers NF, Bergers L, de Groot V, Lazeron RH, van Walderveen 
MA, uitdehaag BM, et al. Concurrent validity of the MS Functional 
Composite using MRI as a biological disease marker. Neurology 
2001; 56: 215–219.
22. Bot JC, Barkhof F, Polman CH, Nijeholt GJ, de Groot V, Bergers 
E, et al. Spinal cord abnormalities in recently diagnosed MS pa-
tients: added value of spinal MRI examination. Neurology 2004; 
62: 226–233.
23. Wallston kA, Wallston BS, deVellis R. development of the mul-
tidimensional health locus of control scales. Health Educ Monogr 
1978; 6: 160–170.
24. Sanderman R, Arrindell WA, Ranchor AV, Eysenck HJ, Eysenck 
SBG. Eysenck Personality Questionnaire (EPQ). Groningen: 
Noordelijk Centrum voor Gezondheidsvraagstukken Rijksuniver-
siteit Groningen, 1997.
25. Van Sonderen E. Sociale Steun Lijst – Interakties (SSL-I) en So-
ciale Steun Lijst – discrepanties (SSL-d). Groningen: Noordelijk 
Centrum voor Gezondheidsvraagstukken Rijksuniversiteit Gron-
ingen; 1997.
26. Rao SM, Leo GJ, Bernardin L, unverzagt F. Cognitive dysfunc-
tion in multiple sclerosis. I. Frequency, patterns, and prediction. 
Neurology 1991; 41: 685–691.
27. krupp LB, LaRocca NG, Muir-Nash J, Steinberg Ad. The fatigue 
severity scale. Application to patients with multiple sclerosis 
and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121–
1123.
28. Lyle RC. A performance test for assessment of upper limb function 
in physical rehabilitation treatment and research. Int J Rehabil Res 
1981; 4: 483–492.
29. Cutter GR, Baier ML, Rudick RA, Cookfair dL, Fischer JS, 
Petkau J, et al. development of a multiple sclerosis functional 
composite as a clinical trial outcome measure. Brain 1999; 122: 
871–882.
30. Rossier P, Wade dT. Validity and reliability comparison of 4 mobil-
ity measures in patients presenting with neurologic impairment. 
Arch Phys Med Rehabil 2001; 82: 9–13.
31. Zeger SL, Liang kY. Longitudinal data analysis for discrete and 
continuous outcomes. Biometrics 1986; 42: 121–130.
32. Twisk JW. Longitudinal data analysis. A comparison between 
generalized estimating equations and random coefficient analysis. 
Eur J Epidemiol 2004; 19: 769–776.
33. Steyerberg EW, Eijkemans MJ, Habbema Jd. Stepwise selection 
in small data sets: a simulation study of bias in logistic regression 
analysis. J Clin Epidemiol 1999; 52: 935–942.
34. Twisk JW, editor. Applied longitudinal data analysis for epidemiol-
ogy: a practical guide. 1 edn. Cambridge: Cambridge university 
Press; 2003.
35. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, d’Amico R, 
et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane 
database Syst Rev 2001; Cd002002.
36. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, d’Amico 
R, et al. Interferons in relapsing remitting multiple sclerosis: a 
systematic review. Lancet 2003; 361: 545–552.
37. krupp LB, Christodoulou C. Fatigue in multiple sclerosis. Curr 
Neurol Neurosci Rep 2001; 1: 294–298.
38. Lazeron RH, Boringa JB, Schouten M, uitdehaag BM, Bergers E, 
Lindeboom J, et al. Brain atrophy and lesion load as explaining 
parameters for cognitive impairment in multiple sclerosis. Mult 
Scler 2005; 11: 524–531.
39. Mathiowetz VG, Finlayson ML, Matuska kM, Chen HY, Luo 
P. Randomized controlled trial of an energy conservation 
course for persons with multiple sclerosis. Mult Scler 2005; 11: 
592–601.
40. Petajan JH, Gappmaier E, White AT, Spencer Mk, Mino L, Hicks 
RW. Impact of aerobic training on fitness and quality of life in 
multiple sclerosis. Ann Neurol 1996; 39: 432–441.
41. Hogan BE, Linden W, Najarian B. Social support interventions 
– do they work? Clin Psychol Rev 2002; 22: 381–440.
42. Freeman JA, Langdon dW, Hobart JC, Thompson AJ. The impact 
of inpatient rehabilitation on progressive multiple sclerosis. Ann 
Neurol 1997; 42: 236–244.
43. Patti F, Ciancio MR, Reggio E, Lopes R, Palermo F, Cacopardo 
M, et al. The impact of outpatient rehabilitation on quality of life 
in multiple sclerosis. J Neurol 2002; 249: 1027–1033.
44. Pozzilli C, Brunetti M, Amicosante AM, Gasperini C, Ristori G, 
Palmisano L, et al. Home based management in multiple sclero-
sis: results of a randomised controlled trial. J Neurol Neurosurg 
Psychiatry 2002; 73: 250–255.
J Rehabil Med 40
